76263-11-1

Basic information

• Product Name: ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE
• Synonyms: ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE;ETHYL 2-AMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE-4-CARBOXYLATE;Ethyl 2-amino-4,5,6,7-tetrahydrobenzothiazole-4-;2-Amino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid ethyl ester;ethyl 2-amino-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxylate
• CAS NO: 76263-11-1
• Molecular Formula: C₁₀H₁₄N₂O₂S
• Molecular Weight: 226.29536
• Mol File: 76263-11-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 173-174
• Boiling Point: 381.014 °C at 760 mmHg
• Flash Point: 184.231 °C
• Appearance: /
• Density: 1.29 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• PKA: 5.05±0.40(Predicted)
• CAS DataBase Reference: ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE(76263-11-1)
• EPA Substance Registry System: ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE(76263-11-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 76263-11-1(Hazardous Substances Data)

Usage

General Description

ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE is a chemical compound with a molecular formula C12H16N2O2S. This substance falls under the category of organosulfur compounds, which are organic compounds that contain sulfur. It is characterized by a tetrahydrobenzothiazole core with an amino, ethyl carboxylate groups attached. Its properties and uses have not been widely studied or documented, so further research would be required to identify its potential applications. Like many chemicals, handling and disposal should be conducted according to established safety procedures to avoid potential hazards or health risks.

InChI:InChI=1/C10H14N2O2S/c1-2-14-9(13)6-4-3-5-7-8(6)12-10(11)15-7/h6H,2-5H2,1H3,(H2,11,12)

Upstream product

• 30132-23-1 ethyl 3-bromo-2-oxocyclohexanecarboxylate 
• 17356-08-0 thiourea 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 

Downstream Products

• 405071-51-4 toluene-4-sulfonic acid 2-amino-4,5,6,7-tetrahydro-benzothiazol-4-ylmethyl ester 
• 1190391-84-4 2-((tert-butoxycarbonyl)amino)-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxylic acid 
• 1558057-84-3 C₃₆H₄₆N₄O₆S 
• 1558057-83-2 C₃₆H₄₆N₄O₆S 
• 1190389-26-4 C₂₆H₃₀N₄O₂S 
• 1190389-25-3 (R)-2-amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxamide 
• 1369897-34-6 ethyl 2-((tert-butoxycarbonyl)amino)-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxylate 
• 729590-69-6 2-bromo-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid ethyl ester 
• 882490-35-9 (S)-4-((di-o-tolylphosphino)methyl)-2-phenyl-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-26-8 (S)-4-((diphenylphosphino)methyl)-2-phenyl-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-20-2 (S)-(2-phenyl-4,5,6,7-tetrahydrobenzo[d]thiazol-4-yl)methyl 4-methylbenzenesulfonate 
• 882490-37-1 (S)-4-((di-o-tolylphosphino)methyl)-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-36-0 (S)-4-((diphenylphosphino)methyl)-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-31-5 (S)-(4,5,6,7-tetrahydrobenzo[d]thiazol-4-yl)methyl 4-methylbenzenesulfonate 

Relevant articles and documents

Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder

A series of conformationally restricted acetanilides were synthesized and evaluated as β3-adrenergic receptor agonists (β3-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine β3-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent β3-AR mediated responses in a rat bladder hyperactivity model.

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.